New Colonoscopes Are Launched: Designed to Find More Disease and Improve Treatment Capabilities

New colonoscopes designed to find more disease and improve treatment capabilities have been launched by Olympus.

Colonscopes, PCF-H190T and the PCF-HQ190 have received 510 (k) clearance. Olympus is a market leader in products to enable minimally invasive treatments such as Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection procedures that can benefit from the use of state-of-the-art endoscopes. The benefits of HQ Dual Focus imaging and imaging modalities like Narrow Band Imaging (NBI), now available through a smaller diameter colonoscope, combine with capabilities such as retroflexion, to advance procedures and improve colonoscopy.

“With these GI endoscopes, Olympus continues to raise the bar on increased functionality, bringing the market a slimmer diameter endoscope, all while providing imaging excellence toward future innovations,” said Kevin Mancini, Vice President for Endoscopy at Olympus America Inc. “We know our physician customers are excited about these advancements that will improve their access and visualization of the anatomy as well as a growing range of treatment modalities.”

  • The new PCF-H190TL/I endoscope is a slim, short-bending scope that allows for tighter angulation without compromise to the passage of treatment accessories. Used with the EVIS EXERA III imaging platform, the PCF-H190TL/I is an HD device with a 510(k) claim for Narrow Band Imaging (NBI), which indicates NBI as a “high confidence” assist to an experienced endoscopist employing a validated polyp classification system such as the NBI International Colorectal Endoscopic (NICE) classification, aiding in distinguishing diminutive adenomatous polyps from non-adenomatous polyps during colonoscopy. Other features include:
    • Better retroflexion capability, a technique associated with improved adenoma detection rate (ADR).
    • Appropriate channel layout for passage of therapeutic accessories, such as for hemostasis or polypectomy.
    • Improved insertability to minimize patient discomfort.
  • The new PCF-HQ190L/I is equipped with Dual Focus technology for increased mucosal visualization. Used with the EVIS EXERA III imaging platform, the endoscope’s NBI plus its near focus mode is associated with a greater than 90% agreement with pathological analysis in assigning post-polypectomy surveillance following colonoscopy. Other features include:
    • A 170-degree angle of view and a new level of resolving power to support detailed observation and facilitate lesion detection.
    • Responsive Insertion Technology (RIT) to facilitate complete colonoscopies and reduced cecal intubation times through better maneuverability.
    • Built-in ScopeGuide Function to provide real-time 3D visualization of the scope’s position and configuration during insertion, including identification of scope loops as they form.

“Our practice benefits from different endoscopes for different applications,” said Peter V. Draganov, MD, professor of medicine and the director of advanced therapeutic endoscopy at the University of Florida Health, Gainesville, FL. “We are pleased that Olympus continues to fortify its offerings with design, imaging and therapeutic advancements. These short-bending endoscopes are exciting for their potential to drive ADR rates down across the industry.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Led by researchers at NYU Grossman School of Medicine, the study results add to evidence that neighboring brain regions, the inferior frontal gyrus and the motor cortex, play an important role in such planning before words are said aloud. Both are part of the folded top layers of the brain, or cerebral cortex, which has long been known to control the muscle (motor) movements in the throat and mouth needed to produce speech. Less clear until now was how closely these regions determine the mix of sounds and words people want to say aloud, the authors report.
PolarisAR describes STELLAR Knee as a mixed-reality surgical navigation platform that guides TKA procedures by displaying measured and computed data overlaid directly in a 3D environment. The mixed-reality system acts as a spatial computer, creating continuous data exchange between the surgeon and the software to help enhance surgical decision-making while simplifying operating room workflow.
This February, the first enrolled patient underwent open surgical aortic arch reconstruction at the University of Pennsylvania, Presbyterian Medical Center, Philadelphia, PA.  During the surgery, the Duett Vascular Graft System was successfully deployed to connect the native left common carotid artery to the surgical graft.
"Our ultra low insertion loss Athermal AWG Multiplexers along with temperature-hardened low-drift AAWG specifically designed for the industrial temperature applications will be marketed aggressively through partnership companies in the East Asia and EU regions after its success in the North America," says Dr. Donald Yu, CMO of POINTek, who runs global marketing operations from Los Angeles, California.
AUX-001 is an innovative, once-daily, extended-release formulation of Nicorandil. For decades, immediate-release, twice daily Nicorandil has been a cornerstone treatment for chronic angina symptoms outside the US, distinguished by its dual mechanism of action that targets both the micro- and macrovascular coronary artery flow bed, and providing sustained angina symptom relief without the common issue of tachyphylaxis seen with other anti-anginal vasodilators like long-acting nitrates. AUX-001 offers efficacy comparable to conventional anti-anginal medications such as beta-blockers, calcium channel blockers, and long-acting nitrates while also potentially enhancing control of the underlying coronary disease and reducing angina related hospitalizations.

By using this website you agree to accept Medical Device News Magazine Privacy Policy